NSE · BSE · Real-time
High-value corporate events — new orders, fund raises, capacity expansions, and earning calls — analysed by AI the moment they hit the exchange.
Lupin Limited's wholly owned subsidiary, VISUfarma B.V., has secured exclusive commercialization rights for YUVEZZI, an innovative eye drop for presbyopia, across Europe and the UK. The agreement with Visus Therapeutics involves a total potential consideration of 75 million euros plus tiered royalties.
Real-time NSE & BSE event alerts, AI-summarized filings, and instant order-win signals — free for 15 days, no card required.
